Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Tester tillegg av AZD6738 (Ceralasertib) til immunterapi for å øke tiden uten kreft for pasienter med ikke-småcellet lungekreft

18. september 2026 oppdatert av: National Cancer Institute (NCI)

En randomisert fase III-studie av sjekkpunktblokade hos lungekreftpasienter i adjuvant setting basert på patologisk respons etter neoadjuvant terapi (CLEAR)

This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.

Studieoversikt

Detaljert beskrivelse

PRIMARY OBJECTIVE:

I. To assess for improvement in disease free survival (DFS) in patients who do not achieve pathologic complete response (pCR) following neoadjuvant therapy and patients who receive adjuvant combination immunotherapy with durvalumab and AZD6738 (ceralasertib) compared to those who receive monotherapy with durvalumab.

SECONDARY OBJECTIVE:

I. To evaluate any difference in overall survival (OS) with patients who receive durvalumab and AZD6738 (ceralasertib) compared to those who receive monotherapy with durvalumab.

EXPLORATORY OBJECTIVES:

I. To evaluate any difference in disease free survival (DFS) with patients who receive durvalumab and AZD6738 (ceralasertib) compared to those who receive monotherapy with durvalumab according to PD-L1, stage, prior immune checkpoint inhibitor (ICI) type, and histology.

II. To evaluate any difference in overall survival (OS) with patients who receive durvalumab and AZD6738 (ceralasertib) compared to those who receive monotherapy with durvalumab according to PD-L1, stage, prior ICI type, and histology.

CORRELATIVE OBJECTIVE:

I. To perform correlative analyses on tissue and blood biospecimens collected within this trial.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Starting 4-12 weeks after surgery, patients receive durvalumab intravenously (IV) over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan and blood sample collection throughout the study and may undergo echocardiography as clinically indicated.

ARM B: Starting 4-12 weeks after surgery, patients receive AZD6738 orally (PO) twice daily (BID) on days 1-7 and durvalumab IV over 60 minutes on day 8 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and blood sample collection throughout the study and may undergo echocardiography as clinically indicated.

After completion of study treatment, patients are followed up every 12 weeks for 2 years then every 24 weeks until year 5 then every 12 months until 10 years from randomization.

Studietype

Intervensjonell

Registrering (Antatt)

630

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Arkansas
      • Jonesboro, Arkansas, Forente stater, 72401
        • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
    • California
      • Beverly Hills, California, Forente stater, 90211
        • Tower Cancer Research Foundation
      • Los Angeles, California, Forente stater, 90048
        • Cedars-Sinai Medical Center
      • Tarzana, California, Forente stater, 91356
        • Cedars-Sinai Cancer - Tarzana
      • Torrance, California, Forente stater, 90505
        • Torrance Memorial Physician Network - Cancer Care
    • Connecticut
      • Hartford, Connecticut, Forente stater, 06102
        • Hartford Hospital
      • Meriden, Connecticut, Forente stater, 06451
        • Midstate Medical Center
      • New Britain, Connecticut, Forente stater, 06050
        • The Hospital of Central Connecticut
    • Delaware
      • Millville, Delaware, Forente stater, 19967
        • Beebe South Coastal Health Campus
      • Newark, Delaware, Forente stater, 19713
        • Helen F Graham Cancer Center
      • Newark, Delaware, Forente stater, 19713
        • Medical Oncology Hematology Consultants PA
      • Rehoboth Beach, Delaware, Forente stater, 19971
        • Beebe Health Campus
    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 20010
        • MedStar Washington Hospital Center
      • Washington D.C., District of Columbia, Forente stater, 20007
        • MedStar Georgetown University Hospital
    • Georgia
      • Atlanta, Georgia, Forente stater, 30308
        • Emory University Hospital Midtown
      • Atlanta, Georgia, Forente stater, 30322
        • Emory University Hospital/Winship Cancer Institute
      • Atlanta, Georgia, Forente stater, 30342
        • Emory Saint Joseph's Hospital
      • Decatur, Georgia, Forente stater, 30033
        • Emory Decatur Hospital
      • Johns Creek, Georgia, Forente stater, 30097
        • Emory Johns Creek Hospital
    • Idaho
      • Boise, Idaho, Forente stater, 83712
        • Saint Luke's Cancer Institute - Boise
      • Coeur d'Alene, Idaho, Forente stater, 83814
        • Kootenai Health - Coeur d'Alene
      • Fruitland, Idaho, Forente stater, 83619
        • Saint Luke's Cancer Institute - Fruitland
      • Meridian, Idaho, Forente stater, 83642
        • Saint Luke's Cancer Institute - Meridian
      • Nampa, Idaho, Forente stater, 83687
        • Saint Alphonsus Cancer Care Center-Nampa
      • Nampa, Idaho, Forente stater, 83687
        • Saint Luke's Cancer Institute - Nampa
      • Post Falls, Idaho, Forente stater, 83854
        • Kootenai Clinic Cancer Services - Post Falls
      • Sandpoint, Idaho, Forente stater, 83864
        • Kootenai Clinic Cancer Services - Sandpoint
    • Illinois
      • Bloomington, Illinois, Forente stater, 61704
        • Illinois CancerCare-Bloomington
      • Canton, Illinois, Forente stater, 61520
        • Illinois CancerCare-Canton
      • Carthage, Illinois, Forente stater, 62321
        • Illinois CancerCare-Carthage
      • Chicago, Illinois, Forente stater, 60611
        • Northwestern University
      • DeKalb, Illinois, Forente stater, 60115
        • Northwestern Medicine Cancer Center Kishwaukee
      • Decatur, Illinois, Forente stater, 62526
        • Decatur Memorial Hospital
      • Decatur, Illinois, Forente stater, 62526
        • Cancer Care Specialists of Illinois - Decatur
      • Dixon, Illinois, Forente stater, 61021
        • Illinois CancerCare-Dixon
      • Effingham, Illinois, Forente stater, 62401
        • Crossroads Cancer Center
      • Eureka, Illinois, Forente stater, 61530
        • Illinois CancerCare-Eureka
      • Galesburg, Illinois, Forente stater, 61401
        • Illinois CancerCare-Galesburg
      • Geneva, Illinois, Forente stater, 60134
        • Northwestern Medicine Cancer Center Delnor
      • Glenview, Illinois, Forente stater, 60026
        • Northwestern Medicine Glenview Outpatient Center
      • Grayslake, Illinois, Forente stater, 60030
        • Northwestern Medicine Grayslake Outpatient Center
      • Kewanee, Illinois, Forente stater, 61443
        • Illinois CancerCare-Kewanee Clinic
      • Lake Forest, Illinois, Forente stater, 60045
        • Northwestern Medicine Lake Forest Hospital
      • Macomb, Illinois, Forente stater, 61455
        • Illinois CancerCare-Macomb
      • Maywood, Illinois, Forente stater, 60153
        • Loyola University Medical Center
      • O'Fallon, Illinois, Forente stater, 62269
        • Cancer Care Center of O'Fallon
      • O'Fallon, Illinois, Forente stater, 62269
        • HSHS Saint Elizabeth's Hospital
      • Oak Brook, Illinois, Forente stater, 60523
        • Northwestern Medicine Oak Brook
      • Orland Park, Illinois, Forente stater, 60462
        • Northwestern Medicine Orland Park
      • Ottawa, Illinois, Forente stater, 61350
        • Illinois CancerCare-Ottawa Clinic
      • Pekin, Illinois, Forente stater, 61554
        • Illinois CancerCare-Pekin
      • Peoria, Illinois, Forente stater, 61615
        • Illinois CancerCare-Peoria
      • Peru, Illinois, Forente stater, 61354
        • Illinois CancerCare-Peru
      • Princeton, Illinois, Forente stater, 61356
        • Illinois CancerCare-Princeton
      • Springfield, Illinois, Forente stater, 62702
        • Southern Illinois University School of Medicine
      • Springfield, Illinois, Forente stater, 62702
        • Springfield Clinic
      • Springfield, Illinois, Forente stater, 62781
        • Springfield Memorial Hospital
      • Warrenville, Illinois, Forente stater, 60555
        • Northwestern Medicine Cancer Center Warrenville
      • Washington, Illinois, Forente stater, 61571
        • Illinois CancerCare - Washington
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46202
        • Indiana University/Melvin and Bren Simon Cancer Center
    • Kansas
      • El Dorado, Kansas, Forente stater, 67042
        • Cancer Center of Kansas - El Dorado
      • Lawrence, Kansas, Forente stater, 66044
        • Lawrence Memorial Hospital
      • Newton, Kansas, Forente stater, 67114
        • Cancer Center of Kansas - Newton
      • Olathe, Kansas, Forente stater, 66061
        • The University of Kansas Cancer Center - Olathe
      • Salina, Kansas, Forente stater, 67401
        • Salina Regional Health Center
      • Topeka, Kansas, Forente stater, 66606
        • University of Kansas Health System Saint Francis Campus
      • Wellington, Kansas, Forente stater, 67152
        • Cancer Center of Kansas - Wellington
      • Wichita, Kansas, Forente stater, 67214
        • Ascension Via Christi Hospitals Wichita
      • Wichita, Kansas, Forente stater, 67208
        • Cancer Center of Kansas-Wichita Medical Arts Tower
      • Wichita, Kansas, Forente stater, 67214
        • Cancer Center of Kansas - Wichita
      • Winfield, Kansas, Forente stater, 67156
        • Cancer Center of Kansas - Winfield
    • Maryland
      • Baltimore, Maryland, Forente stater, 21201
        • University of Maryland/Greenebaum Cancer Center
      • Glen Burnie, Maryland, Forente stater, 21061
        • UM Baltimore Washington Medical Center/Tate Cancer Center
    • Massachusetts
      • Beverly, Massachusetts, Forente stater, 01915
        • Beverly Hospital
      • Burlington, Massachusetts, Forente stater, 01805
        • Lahey Clinic
      • Gloucester, Massachusetts, Forente stater, 01930
        • Addison Gilbert Hospital
      • Peabody, Massachusetts, Forente stater, 01960
        • Lahey Clinic Peabody
      • Springfield, Massachusetts, Forente stater, 01199
        • Baystate Medical Center
    • Michigan
      • Battle Creek, Michigan, Forente stater, 49017
        • Bronson Battle Creek
      • Brighton, Michigan, Forente stater, 48114
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
      • Canton, Michigan, Forente stater, 48188
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
      • Chelsea, Michigan, Forente stater, 48118
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
      • Flint, Michigan, Forente stater, 48503
        • Hurley Medical Center
      • Flint, Michigan, Forente stater, 48503
        • Genesee Hematology Oncology PC
      • Flint, Michigan, Forente stater, 48503
        • Genesys Hurley Cancer Institute
      • Flint, Michigan, Forente stater, 48503
        • Cancer Hematology Centers - Flint
      • Grand Rapids, Michigan, Forente stater, 49503
        • Trinity Health Grand Rapids Hospital
      • Grand Rapids, Michigan, Forente stater, 49503
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
      • Kalamazoo, Michigan, Forente stater, 49007
        • West Michigan Cancer Center
      • Kalamazoo, Michigan, Forente stater, 49007
        • Bronson Methodist Hospital
      • Lansing, Michigan, Forente stater, 48912
        • University of Michigan Health - Sparrow Lansing
      • Livonia, Michigan, Forente stater, 48154
        • Trinity Health Saint Mary Mercy Livonia Hospital
      • Muskegon, Michigan, Forente stater, 49444
        • Trinity Health Muskegon Hospital
      • Niles, Michigan, Forente stater, 49120
        • Corewell Health Lakeland Hospitals - Niles Hospital
      • Norton Shores, Michigan, Forente stater, 49444
        • Cancer and Hematology Centers of Western Michigan - Norton Shores
      • Pontiac, Michigan, Forente stater, 48341
        • Trinity Health Saint Joseph Mercy Oakland Hospital
      • Reed City, Michigan, Forente stater, 49677
        • Corewell Health Reed City Hospital
      • Saint Joseph, Michigan, Forente stater, 49085
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
      • Saint Joseph, Michigan, Forente stater, 49085
        • Corewell Health Lakeland Hospitals - Saint Joseph Hospital
      • Traverse City, Michigan, Forente stater, 49684
        • Munson Medical Center
      • Wyoming, Michigan, Forente stater, 49519
        • University of Michigan Health - West
      • Ypsilanti, Michigan, Forente stater, 48197
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
    • Minnesota
      • Brainerd, Minnesota, Forente stater, 56401
        • Essentia Health Saint Joseph's Medical Center
      • Coon Rapids, Minnesota, Forente stater, 55433
        • Mercy Hospital
      • Deer River, Minnesota, Forente stater, 56636
        • Essentia Health - Deer River Clinic
      • Duluth, Minnesota, Forente stater, 55805
        • Essentia Health Cancer Center
      • Edina, Minnesota, Forente stater, 55435
        • Fairview Southdale Hospital
      • Hibbing, Minnesota, Forente stater, 55746
        • Essentia Health Hibbing Clinic
      • Minneapolis, Minnesota, Forente stater, 55407
        • Abbott-Northwestern Hospital
      • Minneapolis, Minnesota, Forente stater, 55417
        • Minneapolis VA Medical Center
      • Saint Louis Park, Minnesota, Forente stater, 55416
        • Park Nicollet Clinic - Saint Louis Park
      • Saint Paul, Minnesota, Forente stater, 55101
        • Regions Hospital
      • Saint Paul, Minnesota, Forente stater, 55102
        • United Hospital
      • Sandstone, Minnesota, Forente stater, 55072
        • Essentia Health Sandstone
      • Virginia, Minnesota, Forente stater, 55792
        • Essentia Health Virginia Clinic
    • Mississippi
      • Columbus, Mississippi, Forente stater, 39705
        • Baptist Memorial Hospital and Cancer Center-Golden Triangle
      • Grenada, Mississippi, Forente stater, 38901
        • Baptist Cancer Center-Grenada
      • New Albany, Mississippi, Forente stater, 38652
        • Baptist Memorial Hospital and Cancer Center-Union County
      • Oxford, Mississippi, Forente stater, 38655
        • Baptist Memorial Hospital and Cancer Center-Oxford
      • Southhaven, Mississippi, Forente stater, 38671
        • Baptist Memorial Hospital and Cancer Center-Desoto
    • Missouri
      • Cape Girardeau, Missouri, Forente stater, 63703
        • Saint Francis Medical Center
      • Farmington, Missouri, Forente stater, 63640
        • Parkland Health Center - Farmington
      • Sainte Genevieve, Missouri, Forente stater, 63670
        • Sainte Genevieve County Memorial Hospital
      • St Louis, Missouri, Forente stater, 63131
        • Missouri Baptist Medical Center
      • St Louis, Missouri, Forente stater, 63128
        • Mercy Hospital South
      • Sullivan, Missouri, Forente stater, 63080
        • Missouri Baptist Sullivan Hospital
    • Montana
      • Anaconda, Montana, Forente stater, 59711
        • Community Hospital of Anaconda
      • Billings, Montana, Forente stater, 59101
        • Billings Clinic Cancer Center
      • Billings, Montana, Forente stater, 59102
        • Saint Vincent Frontier Cancer Center
      • Bozeman, Montana, Forente stater, 59715
        • Bozeman Health Deaconess Hospital
      • Great Falls, Montana, Forente stater, 59405
        • Benefis Sletten Cancer Institute
      • Missoula, Montana, Forente stater, 59804
        • Community Medical Center
    • New Hampshire
      • Concord, New Hampshire, Forente stater, 03301
        • New Hampshire Oncology Hematology PA-Concord
      • Manchester, New Hampshire, Forente stater, 03103
        • Solinsky Center for Cancer Care
    • New Jersey
      • Flemington, New Jersey, Forente stater, 08822
        • Hunterdon Medical Center
    • New York
      • Glens Falls, New York, Forente stater, 12801
        • Glens Falls Hospital
      • The Bronx, New York, Forente stater, 10461
        • Montefiore Medical Center-Einstein Campus
    • North Carolina
      • Pinehurst, North Carolina, Forente stater, 28374
        • FirstHealth of the Carolinas-Moore Regional Hospital
    • North Dakota
      • Fargo, North Dakota, Forente stater, 58103
        • Essentia Health Cancer Center-South University Clinic
    • Ohio
      • Canton, Ohio, Forente stater, 44710
        • Aultman Health Foundation
      • Columbus, Ohio, Forente stater, 43210
        • Ohio State University Comprehensive Cancer Center
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73104
        • University of Oklahoma Health Sciences Center
    • Oregon
      • Newberg, Oregon, Forente stater, 97132
        • Providence Newberg Medical Center
      • Oregon City, Oregon, Forente stater, 97045
        • Providence Willamette Falls Medical Center
      • Portland, Oregon, Forente stater, 97239
        • Oregon Health and Science University
      • Portland, Oregon, Forente stater, 97213
        • Providence Portland Medical Center
      • Portland, Oregon, Forente stater, 97225
        • Providence Saint Vincent Medical Center
    • Pennsylvania
      • Allentown, Pennsylvania, Forente stater, 18103
        • Lehigh Valley Hospital-Cedar Crest
      • Bethlehem, Pennsylvania, Forente stater, 18017
        • Lehigh Valley Hospital - Muhlenberg
      • Bryn Mawr, Pennsylvania, Forente stater, 19010
        • Bryn Mawr Hospital
      • East Stroudsburg, Pennsylvania, Forente stater, 18301
        • Pocono Medical Center
      • Erie, Pennsylvania, Forente stater, 16505
        • UPMC Hillman Cancer Center Erie
      • Greensburg, Pennsylvania, Forente stater, 15601
        • UPMC Cancer Centers - Arnold Palmer Pavilion
      • Harrisburg, Pennsylvania, Forente stater, 17109
        • UPMC Pinnacle Cancer Center/Community Osteopathic Campus
      • Hazleton, Pennsylvania, Forente stater, 18201
        • Lehigh Valley Hospital-Hazleton
      • Mechanicsburg, Pennsylvania, Forente stater, 17050
        • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
      • Media, Pennsylvania, Forente stater, 19063
        • Riddle Memorial Hospital
      • Monroeville, Pennsylvania, Forente stater, 15146
        • UPMC Hillman Cancer Center - Monroeville
      • Paoli, Pennsylvania, Forente stater, 19301
        • Paoli Memorial Hospital
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • University of Pennsylvania/Abramson Cancer Center
      • Pittsburgh, Pennsylvania, Forente stater, 15232
        • UPMC Hillman Cancer Center
      • Pittsburgh, Pennsylvania, Forente stater, 15243
        • UPMC-Saint Clair Hospital Cancer Center
      • West Reading, Pennsylvania, Forente stater, 19611
        • Reading Hospital
      • Wynnewood, Pennsylvania, Forente stater, 19096
        • Lankenau Medical Center
    • South Carolina
      • Georgetown, South Carolina, Forente stater, 29440
        • Tidelands Georgetown Memorial Hospital
    • Tennessee
      • Collierville, Tennessee, Forente stater, 38017
        • Baptist Memorial Hospital and Cancer Center-Collierville
      • Memphis, Tennessee, Forente stater, 38120
        • Baptist Memorial Hospital and Cancer Center-Memphis
      • Nashville, Tennessee, Forente stater, 37232
        • Vanderbilt University/Ingram Cancer Center
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22908
        • University of Virginia Cancer Center
      • Fredericksburg, Virginia, Forente stater, 22408
        • Hematology Oncology Associates of Fredericksburg Inc
      • Richmond, Virginia, Forente stater, 23235
        • VCU Massey Cancer Center at Stony Point
      • Richmond, Virginia, Forente stater, 23229
        • Virginia Cancer Institute
      • Richmond, Virginia, Forente stater, 23298
        • VCU Massey Comprehensive Cancer Center
      • South Hill, Virginia, Forente stater, 23970
        • VCU Community Memorial Health Center
    • West Virginia
      • Huntington, West Virginia, Forente stater, 25701
        • Edwards Comprehensive Cancer Center
      • Morgantown, West Virginia, Forente stater, 26506
        • West Virginia University Healthcare
      • Parkersburg, West Virginia, Forente stater, 26101
        • Camden Clark Medical Center
    • Wisconsin
      • Antigo, Wisconsin, Forente stater, 54409
        • Aspirus Cancer Care-Antigo-Volm Cancer Center
      • Appleton, Wisconsin, Forente stater, 54911
        • ThedaCare Regional Cancer Center
      • Ashland, Wisconsin, Forente stater, 54806
        • Duluth Clinic Ashland
      • Hayward, Wisconsin, Forente stater, 54843
        • Essentia Health-Hayward Clinic
      • La Crosse, Wisconsin, Forente stater, 54601
        • Gundersen Lutheran Medical Center
      • Medford, Wisconsin, Forente stater, 54451
        • Aspirus Medford Hospital
      • Mukwonago, Wisconsin, Forente stater, 53149
        • ProHealth D N Greenwald Center
      • Oconomowoc, Wisconsin, Forente stater, 53066
        • ProHealth Oconomowoc Memorial Hospital
      • Rhinelander, Wisconsin, Forente stater, 54501
        • Aspirus Cancer Care-Rhinelander-James Beck Cancer Center
      • Spooner, Wisconsin, Forente stater, 54801
        • Essentia Health-Spooner Clinic
      • Stevens Point, Wisconsin, Forente stater, 54481
        • Aspirus Cancer Care - Stevens Point
      • Superior, Wisconsin, Forente stater, 54880
        • Essentia Health Saint Mary's Hospital - Superior
      • Waukesha, Wisconsin, Forente stater, 53188
        • UW Cancer Center at ProHealth Care
      • Wausau, Wisconsin, Forente stater, 54401
        • Aspirus Cancer Care-Wausau
      • Wisconsin Rapids, Wisconsin, Forente stater, 54494
        • Aspirus Cancer Care - Wisconsin Rapids

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • STEP 0: Patient must be >= 18 years of age

  • STEP 0: Patient must have stage II to select stage IIIB (N2 but excluding N3) non-small cell lung cancer (NSCLC) of any histology using International Association for the Study of Lung Cancer (IASLC) 8th edition. Stage is assessed at time of initiating pre-operative chemo-immunotherapy

  • STEP 0: Patient must fall into one of the following categories:

    • Planning to undergo, be currently undergoing, or recently completed any standard of care neoadjuvant chemo-immunotherapy with plans to undergo surgical resection
    • Recently completed any standard of care neoadjuvant chemo-immunotherapy AND completed surgical resection and are awaiting pCR status.
    • Recently completed any standard of care neoadjuvant chemo-immunotherapy AND completed surgical resection with confirmed non-path complete response (CR) status.

NOTES:

  • Patient must have completed at least 3 cycles of neoadjuvant chemo-immunotherapy before surgery in order to be eligible for Step 1 randomization.

  • Patients who have completed their surgical resection prior to enrollment in step 0 registration must have their surgery date within a window that will allow initiation of EA5231 treatment (cycle 1 day 1) to commence within 4-12 weeks following surgery

    • STEP 1: EA5231 CLEAR randomization for patients without a pCR post-surgery. Patient's with pCR after surgery will be offered to enroll in the SWOG study S2414 INSIGHT instead
    • STEP 1: Patient must have completed R0 resection after standard of care neoadjuvant chemo-immunotherapy (minimum three cycles completed) for stage II to select stage IIIB (N2 but excluding N3) non-small cell lung cancer (NSCLC) of any histology using IASLC 8th Edition
    • STEP 1: Patient must have non-pathological CR status post-surgery. The pathological CR/non-pathological CR status will be determined by local pathology using IASLC criteria and using the surgical sample tissue
    • STEP 1: Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - ≤ 2 (or Karnofsky ≥ 60%)
    • STEP 1: Patient must not have any known EGFR or ALK genetic alterations. Mutation negative status will be determined per local institutional practices and consistent with National Comprehensive Cancer Network (NCCN) guidelines
    • STEP 1: Patient must have undergone a chest CT after surgery and within 28 days prior to step 1 randomization
    • STEP 1: Patient must have recovered from clinically significant adverse events of their most recent therapy/intervention prior to step 1 randomization
    • STEP 1: Patient must not have experienced a toxicity that led to the permanent discontinuation of prior immunotherapy
    • STEP 1: Patient must not be receiving ongoing steroids at a dose of prednisone 10 mg or higher (or equivalent) at the time of step 1 randomization. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication) are allowed. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection) are allowed
    • STEP 1: Patient must not have received or have a plan to receive post-operative radiation therapy (PORT)
    • STEP 1: Patient must not have a history of treatment-related pneumonitis requiring ongoing steroids or supplemental oxygen use
    • STEP 1: Patient must not have a history of interstitial lung disease (ILD)
    • STEP 1: Patient must not have diagnosis of ataxia telangiectasia
    • STEP 1: Patient must not have history of active primary immunodeficiency
    • STEP 1: Patient must not have history of allogenic organ transplantation
    • STEP 1: Patient must have body weight > 30 kg
    • STEP 1: Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to Step 1 randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria:
  • Has achieved menarche at some point

  • Has not undergone a hysterectomy or bilateral oophorectomy

  • Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

    • STEP 1: Patient must not expect to conceive or father children by using highly accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Patients of childbearing potential must use at least 1 highly effective method of contraception in addition to a condom and continue to use it throughout their time on protocol treatment. Male patients must use a condom plus spermicide throughout their time on while on protocol treatment. In addition, all patients must continue contraception use for at least 6 months after the last dose of protocol treatment. Patients must also not breastfeed while on protocol treatment and for at least 6 months after the last dose of protocol treatment. Patients must not donate sperm while on protocol treatment and for 6 months after the last dose of protocol treatment
    • STEP 1: Patient must not donate blood while on protocol treatment
    • STEP 1: Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
    • STEP 1: Leukocytes ≥ 3,000/mcL (these labs must be obtained ≤ 28 days prior to step 1 randomization)
    • STEP 1: Hemoglobin ≥ 9.0 g/dL (these labs must be obtained ≤ 28 days prior to step 1 randomization)
    • STEP 1: Absolute neutrophil count (ANC) ≥ 1,500/mcL (these labs must be obtained ≤ 28 days prior to step 1 randomization)
    • STEP 1: Platelets ≥ 100,000/mcL (these labs must be obtained ≤ 28 days prior to step 1 randomization)
    • STEP 1: Total bilirubin ≤ institutional upper limit of normal (ULN) (these labs must be obtained ≤ 28 days prior to step 1 randomization)
    • STEP 1: Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3.0 × institutional ULN (these labs must be obtained ≤ 28 days prior to step 1 randomization)
    • STEP 1: Creatinine clearance ≥ 50 mL/min (estimated using Cockcroft-Gault method or measured) (these labs must be obtained ≤ 28 days prior to step 1 randomization)
    • STEP 1: Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of step 1 randomization are eligible for this trial
    • STEP 1: For patients with known chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
    • STEP 1: Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
    • STEP 1: Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
    • STEP 1: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
    • STEP 1: Patient must not have received live attenuated vaccine within 30 days prior to the step 1 randomization, while on protocol treatment and within 30 days after the last dose of durvalumab

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Arm A (Durvalumab)

Starting 4-12 weeks after surgery, patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and blood sample collection throughout the study and may undergo echocardiography as clinically indicated.

Undergo blood sample collection

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Undergo CT scan

Andre navn:
  • CT
  • KATT
  • CAT-skanning
  • Beregnet aksial tomografi
  • Datastyrt aksialtomografi
  • Datastyrt tomografi
  • CT skann
  • tomografi
  • Datastyrt aksial tomografi (prosedyre)
  • Datastyrt tomografi (CT) skanning
  • Diagnostisk CAT -skanning
  • Diagnostisk CAT -skannertype

Undergo echocardiography

Andre navn:
  • Ekkokardiografi
  • EC

Given IV

Andre navn:
  • Imfinzi
  • Immunoglobulin G1, Anti-(Humant Protein B7-H1) (Human Monoklonal MEDI4736 Heavy Chain), Disulfid med Human Monoklonal MEDI4736 Kappa-kjede, Dimer
  • MEDI-4736
  • MEDI4736
  • MEDI 4736
Eksperimentell: Arm B (Durvalumab and AZD6738)

Starting 4-12 weeks after surgery, patients receive AZD6738 PO BID on days 1-7 and durvalumab IV over 60 minutes on day 8 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and blood sample collection throughout the study and may undergo echocardiography as clinically indicated.

Undergo blood sample collection

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Undergo CT scan

Andre navn:
  • CT
  • KATT
  • CAT-skanning
  • Beregnet aksial tomografi
  • Datastyrt aksialtomografi
  • Datastyrt tomografi
  • CT skann
  • tomografi
  • Datastyrt aksial tomografi (prosedyre)
  • Datastyrt tomografi (CT) skanning
  • Diagnostisk CAT -skanning
  • Diagnostisk CAT -skannertype

Undergo echocardiography

Andre navn:
  • Ekkokardiografi
  • EC

Given IV

Andre navn:
  • Imfinzi
  • Immunoglobulin G1, Anti-(Humant Protein B7-H1) (Human Monoklonal MEDI4736 Heavy Chain), Disulfid med Human Monoklonal MEDI4736 Kappa-kjede, Dimer
  • MEDI-4736
  • MEDI4736
  • MEDI 4736

Given PO

Andre navn:
  • AZD6738

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Disease free survival (DFS)
Tidsramme: From randomization to the earliest event defined as the first recurrence of non-small cell lung cancer (NSCLC), any new lung cancer or death, up to 10 years

Will estimate DFS distributions using the Kaplan-Meier method and employ Cox proportional hazards models to estimate the treatment hazard ratios. The comparison of DFS will use a logrank test stratified on the randomization stratification factors with a one-sided type I error rate of 2.5%. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates will be accompanied by the corresponding two-sided 95% confidence intervals.

From randomization to the earliest event defined as the first recurrence of non-small cell lung cancer (NSCLC), any new lung cancer or death, up to 10 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall survival (OS)
Tidsramme: From randomization to death from any cause, up to 10 years

Will estimate OS distributions using the Kaplan-Meier method and employ Cox proportional hazards models to estimate the treatment hazard ratios. The comparison of OS will use a logrank test stratified on the randomization stratification factors with a one-sided type I error rate of 2.5%. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates will be accompanied by the corresponding two-sided 95% confidence intervals.

From randomization to death from any cause, up to 10 years
Incidence of adverse events
Tidsramme: Up to 10 years

Toxicity will be assessed by summaries by Common Terminology Criteria for Adverse Event grade.

Up to 10 years

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Korrelative analyser på bioprøver av vev, blod og avføring
Tidsramme: Inntil 10 år
Inntil 10 år
Estimates of treatment effect by sex
Tidsramme: Up to 10 years

Estimates of DFS and the corresponding 95% confidence intervals (CIs) by sex.

Up to 10 years
Estimates of treatment effect by race
Tidsramme: Up to 10 years

Estimates of DFS and the corresponding 95% CIs by race.

Up to 10 years
Estimates of treatment effect by ethnicity
Tidsramme: Up to 10 years

Estimates of DFS and the corresponding 95% CIs by ethnicity.

Up to 10 years
DFS according to PD-L1 status
Tidsramme: Up to 10 years

Will be compared between treatment arms using the logrank test and Cox modeling.

Up to 10 years
DFS according to stage
Tidsramme: Up to 10 years

Will be compared between treatment arms using the logrank test and Cox modeling.

Up to 10 years
DFS according to prior immune checkpoint inhibitor (ICI) type
Tidsramme: Up to 10 years

Will be compared between treatment arms using the logrank test and Cox modeling.

Up to 10 years
DFS according to histology
Tidsramme: Up to 10 years

Will be compared between treatment arms using the logrank test and Cox modeling.

Up to 10 years
OS according to PD-L1 status
Tidsramme: Up to 10 years

Will be compared between treatment arms using the logrank test and Cox modeling.

Up to 10 years
OS according to stage
Tidsramme: Up to 10 years

Will be compared between treatment arms using the logrank test and Cox modeling.

Up to 10 years
OS according to prior ICI type
Tidsramme: Up to 10 years

Will be compared between treatment arms using the logrank test and Cox modeling.

Up to 10 years
OS according to histology
Tidsramme: Up to 10 years

Will be compared between treatment arms using the logrank test and Cox modeling.

Up to 10 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Dwight H Owen, ECOG-ACRIN Cancer Research Group

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

7. august 2025

Primær fullføring (Antatt)

30. juni 2028

Studiet fullført (Antatt)

30. juni 2028

Datoer for studieregistrering

Først innsendt

12. desember 2024

Først innsendt som oppfylte QC-kriteriene

12. desember 2024

Først lagt ut (Faktiske)

13. desember 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

21. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. september 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere